Chromium Supplementation in Women with Clomiphene Citrate-Resistant Polycystic Ovary Syndrome

Effect of Chromium Supplementation in Women with Clomiphene Citrate-Resistant Polycystic Ovary Syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201611001856174

Enrollment

100

Registered

2016-11-09

Start date

2013-04-07

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female Polycystic Ovarian Syndrome, PCOS

Interventions

clomiphene citrate dose 100mg

Chromium picolinate

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: PCOS Age 18-40 clomiphene citrate resistant Infertile

Exclusion criteria

Exclusion criteria: Thyroid hypo/hyperfunction Hyperprolactinemia Cushing syndrome) Others factors causing infertility Fasting hyperglycemia Elevated liver enzymes History of cardiac disease.

Design outcomes

Primary

Measure	Time frame
ovulation rate after 3-cycle treatment	—

Secondary

Measure	Time frame
Secondary outcome measures were the effect of chromium supplementation on insulin, FSH and LH levels after treatment.	—

Countries

Egypt

Contacts

Public ContactMohamed Mahmoud Mohamed Kotb

Lecturer of Obstetrics and Gynecology- Cairo Universit

kotbmmk@yahoo.com0201000560568

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026